imatinib has been researched along with Innate Inflammatory Response in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, N | 1 |
| Bürli, RW | 1 |
| Neira, S | 1 |
| Hungate, R | 1 |
| Zhang, D | 1 |
| Yu, V | 1 |
| Nguyen, Y | 1 |
| Tudor, Y | 1 |
| Plant, M | 1 |
| Flynn, S | 1 |
| Meagher, KL | 1 |
| Lee, MR | 1 |
| Zhang, X | 1 |
| Itano, A | 1 |
| Schrag, M | 1 |
| Xu, Y | 1 |
| Ng, GY | 1 |
| Hu, E | 1 |
| Li, Y | 1 |
| Lu, X | 1 |
| Ren, X | 1 |
| Ding, K | 1 |
| Guan, B | 1 |
| Jiang, C | 1 |
| Marín-Rubio, JL | 1 |
| Peltier-Heap, RE | 1 |
| Dueñas, ME | 1 |
| Heunis, T | 1 |
| Dannoura, A | 1 |
| Inns, J | 1 |
| Scott, J | 1 |
| Simpson, AJ | 1 |
| Blair, HJ | 1 |
| Heidenreich, O | 1 |
| Allan, JM | 1 |
| Watt, JE | 1 |
| Martin, MP | 1 |
| Saxty, B | 1 |
| Trost, M | 1 |
1 review available for imatinib and Innate Inflammatory Response
| Article | Year |
|---|---|
Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.
Topics: Amino Acid Sequence; Animals; Discoidin Domain Receptors; Drug Discovery; Humans; Inflammation; Liga | 2015 |
3 other studies available for imatinib and Innate Inflammatory Response
| Article | Year |
|---|---|
Discovery of a potent and selective c-Kit inhibitor for the treatment of inflammatory diseases.
Topics: Animals; Chemistry, Pharmaceutical; Drug Design; Histamine Release; Inflammation; Inhibitory Concent | 2008 |
Design and development of 1,3,5-triazine derivatives as protective agent against spinal cord injury in rat via inhibition of NF-ĸB.
Topics: Animals; Drug Design; Gene Expression Regulation; Inflammation; Lipopolysaccharides; Mice; Molecular | 2021 |
A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia.
Topics: Cytokines; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inflammat | 2022 |